NASDAQ:LENZ

LENZ Therapeutics Q2 2025 Earnings Results & Report

LENZ Therapeutics logo
$3.82 -0.31 (-7.51%)
Closing price 04:00 PM Eastern
Extended Trading
$3.87 +0.05 (+1.31%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LENZ Therapeutics beat analyst earnings expectations and met on revenue in its Q2 2025 results, released July 30, 2025. The company reported EPS of -$0.53 versus the -$0.58 consensus estimate, while revenue of $5 million matched the $5 million estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

LENZ Therapeutics EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.58
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

LENZ Therapeutics Revenue Results

Actual Revenue
$5 million
Expected Revenue
$5 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

LENZ Therapeutics Q2 2025 Earnings FAQ

LENZ Therapeutics (NASDAQ:LENZ) reported earnings of -$0.53 per share for Q2 2025, beating the consensus estimate of -$0.58. The report was announced on Wednesday, July 30, 2025.

LENZ Therapeutics reported revenue of $5 million for Q2 2025, against a consensus estimate of $5 million.

LENZ Therapeutics Earnings Headlines

LENZ Therapeutics: Don't Be Tempted With This Value Trap
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
HC Wainwright Has Optimistic Opinion of LENZ FY2026 Earnings
See More LENZ Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email.

About LENZ Therapeutics

LENZ Therapeutics (NASDAQ:LENZ) is a biopharmaceutical company focused on developing treatments for presbyopia, the age-related difficulty focusing on nearby objects. Its lead product, VIZZ (aceclidine ophthalmic solution), is a prescription eye drop approved in the United States for treating presbyopia in adults.

VIZZ is designed to improve near vision by constricting the pupil, which can increase depth of focus. The company’s work centers on developing and commercializing this topical, non-invasive treatment as an alternative to corrective eyewear for people with presbyopia.

LENZ became a publicly traded company in 2024 following a merger with Graphite Bio. Its business is focused on the U.S. market for presbyopia treatments.

View LENZ Therapeutics Profile